RAB, member of RAS oncogene family like 2BGenealiases: []
Q-omics provides the consensus-scored RABL2B profile across patient tissues and cancer cell-line models. RABL2B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RABL2B is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, RABL2B RNA expression shows 19,958 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KICH, and ACC as cancer lineages where RABL2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RABL2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RABL2B survival associations across molecular data types. RABL2B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RABL2B RNA expression–survival associations across cancer types. High RABL2B expression shows unfavorable associations in MESO, LIHC and ACC, but favorable associations in BLCA, UCEC and READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for RABL2B RNA expression.
This table summarizes RABL2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RABL2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RABL2B shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in HNSC, LIHC and STAD. The KICH box plot shows higher RABL2B RNA expression in normal versus tumor tissue (log2 FC = −1.069, t-test p < 0.001).
This table shows molecular features associated with RABL2B in patient tissues and cancer cell lines. In patient samples, RABL2B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RABL2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
